Fritsche HA Jr - Search Results

1

Detection and Prognostic Significance of Circulating Tumor Cells in Patients With Metastatic Thyroid Cancer.

Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA Jr, Cote GJ, Sherman SI. Xu JY, et al. Among authors: fritsche ha jr. J Clin Endocrinol Metab. 2016 Nov;101(11):4461-4467. doi: 10.1210/jc.2016-2567. Epub 2016 Aug 30. J Clin Endocrinol Metab. 2016. PMID: 27575943 Free PMC article.

2

Fenretinide activity in retinoid-resistant oral leukoplakia.

Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA Jr, Zhou X, Papadimitrakopoulou V, Khuri FR, Tran H, Clayman GL, Hittelman WN, Hong WK, Lotan R. Lippman SM, et al. Among authors: fritsche ha jr. Clin Cancer Res. 2006 May 15;12(10):3109-14. doi: 10.1158/1078-0432.CCR-05-2636. Clin Cancer Res. 2006. PMID: 16707609 Clinical Trial.

3

Prospective evaluation of a novel approach for the use of a quantitative galactose oxidase-Schiff reaction in ductal fluid samples from women with breast carcinoma.

Chagpar A, Evelegh M, Fritsche HA Jr, Krishnamurthy S, Hunt KK, Kuerer HM. Chagpar A, et al. Among authors: fritsche ha jr. Cancer. 2004 Jun 15;100(12):2549-54. doi: 10.1002/cncr.20311. Cancer. 2004. PMID: 15197795 Free article. Clinical Trial.

4

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.

Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA Jr, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS. Zinner RG, et al. Among authors: fritsche ha jr. Lung Cancer. 2004 Apr;44(1):99-110. doi: 10.1016/j.lungcan.2003.09.026. Lung Cancer. 2004. PMID: 15013588 Clinical Trial.

5

Potential role for intraoperative gamma probe identification of normal parathyroid glands.

Pederson LC, Shapiro SE, Fritsche HA Jr, Delpassand ES, Gagel RF, Sherman SI, Vassilopoulou-Sellin R, Evans DB, Lee JE. Pederson LC, et al. Among authors: fritsche ha jr. Am J Surg. 2003 Dec;186(6):711-7. doi: 10.1016/j.amjsurg.2003.08.021. Am J Surg. 2003. PMID: 14672784

6

Quality control and peak finding for proteomics data collected from nipple aspirate fluid by surface-enhanced laser desorption and ionization.

Coombes KR, Fritsche HA Jr, Clarke C, Chen JN, Baggerly KA, Morris JS, Xiao LC, Hung MC, Kuerer HM. Coombes KR, et al. Among authors: fritsche ha jr. Clin Chem. 2003 Oct;49(10):1615-23. doi: 10.1373/49.10.1615. Clin Chem. 2003. PMID: 14500586

7

Improving the yield of preoperative parathyroid localization: technetium Tc 99m-sestamibi imaging after thyroid suppression.

Royal RE, Delpassand ES, Shapiro SE, Fritsche HA Jr, Vassilopoulou-Sellin R, Sherman SI, Gagel RF, Evans DB, Lee JE. Royal RE, et al. Among authors: fritsche ha jr. Surgery. 2002 Dec;132(6):968-74; discussion 974-5. doi: 10.1067/msy.2002.128609. Surgery. 2002. PMID: 12490843

8

Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.

Herbst RS, Madden TL, Tran HT, Blumenschein GR Jr, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA Jr, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Herbst RS, et al. Among authors: fritsche ha jr. J Clin Oncol. 2002 Nov 15;20(22):4440-7. doi: 10.1200/JCO.2002.04.006. J Clin Oncol. 2002. PMID: 12431966 Clinical Trial.

9

Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.

Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA Jr, Lotan R, Lu T, Hittelman WN, Bevers TB, Stelling CB, Lippman SM. Singletary SE, et al. Among authors: fritsche ha jr. Clin Cancer Res. 2002 Sep;8(9):2835-42. Clin Cancer Res. 2002. PMID: 12231524 Clinical Trial.

10

The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy.

Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA HA Jr. Babaian RJ, et al. Among authors: fritsche ha ha jr. J Urol. 2001 Mar;165(3):757-60. J Urol. 2001. PMID: 11176461

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

30 results

Search Page